Header Logo

Connection

Kathleen Moore to Genetic Therapy

Back to Details
This is a "connection" page, showing publications Kathleen Moore has written about Genetic Therapy.
Kathleen Moore
Connection Strength
0.130
Genetic Therapy
  1. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 11; 147(2):283-290.
    View in: PubMed
    Score: 0.130
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.